# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT04034758 (Continued)

# Inclusion criteria

- Failure to acquire clinical remission after full dose and adequate course (4 weeks) of 5-ASA or precursor treatment
- Written informed consent (or assent when appropriate, according to institutional guidelines)

# Exclusion criteria

- HIV/AIDS or other severe immunodeficiency
- Severe prior allergic reaction to food or supplementary material of placebo
- Pregnancy or lactation
- CMV or EBV colitis suspected by endoscopic findings and confirmed by immunohistochemistry and biopsy PCR
- Decompensated life-threatening disease including but not restricted to liver cirrhosis (bleeding varices, ascites, encephalopathy, or icterus), myocardial infarction, and malignancy

# Interventions

# Experimental arm

- Oral administration of 30 SQIMC-md capsules containing 2 × 1013 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces + full dose of oral 5-ASA

# Control arm

- Oral administration of 30 placebo capsules containing edible pigmented starch + full dose of oral 5-ASA

# Outcomes

# Primary outcome

- Clinical response rate after SQIMC-md treatment (Mayo score decrease ≥ 3 points and ≥ 30% from baseline, with decrease of ≥ 1 point in subscore for Rectal Bleeding or absolute subscore ≤ 1 for Rectal Bleeding) at week 8

# Secondary outcomes

- Incidence of treatment-emergent adverse events at week 12
- Clinical response rate at weeks 4 and 12
- Clinical remission rate (Mayo score ≤ 2 points and no single score > 1 point) at week 12
- Mean (or median) decrease of fecal calprotectin at week 12
- Mean (or median) change from baseline in IBDQ Total score and subscore at week 12

# Starting date

30 August 2019

# Contact information

Department of Gastroenterology, Tongji Hospital, China

# Notes

# NCT04202211

# Study name

FMT for remission of active ulcerative colitis in adults

# Methods

RCT conducted in Canada

# Participants

# Inclusion criteria

- Active UC (Mayo score > 3 and Mayo Endoscopic subscore > 1, within 30 days of enrollment or at baseline)

# Exclusion criteria

- Severe UC requiring hospitalization at time of enrollment

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.